- Messages
- 76
- Type of diabetes
- Treatment type
- Insulin
- Dislikes
- Being obese.
Novo Nordisk and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK are warning the public and healthcare professionals about the discovery of a small number of counterfeit NovoFine® needles on the UK market.
The needles are not made by Novo Nordisk, the manufacturer of NovoFine® needles and do not comply with the company’s stringent product quality standards. At this point, there is no information indicating that counterfeit needles have been sold in markets outside the UK.
The counterfeit needles are sized Fine 31g x 6mm and have the batch number 08J02S, expiry 08/2013.
The needles are used with Novo Nordisk’s insulin injection pens both the disposable and durable pen types.
Novo Nordisk has carried out a Health Hazard Evaluation which assessed that using the counterfeit product would most likely only cause minor adverse events such as local skin reactions around the injection site.
Novo Nordisk was alerted to the existence of counterfeit products following two customer complaints in England in March. The company immediately informed the local regulatory authorities in the UK, launched an investigation and increased monitoring of complaints.
This article is mentioned on the Diabetes.co.uk Home page, but HERE IS THE DETAILED NOVO NORDISK ARTICLE.
The needles are not made by Novo Nordisk, the manufacturer of NovoFine® needles and do not comply with the company’s stringent product quality standards. At this point, there is no information indicating that counterfeit needles have been sold in markets outside the UK.
The counterfeit needles are sized Fine 31g x 6mm and have the batch number 08J02S, expiry 08/2013.
The needles are used with Novo Nordisk’s insulin injection pens both the disposable and durable pen types.
Novo Nordisk has carried out a Health Hazard Evaluation which assessed that using the counterfeit product would most likely only cause minor adverse events such as local skin reactions around the injection site.
Novo Nordisk was alerted to the existence of counterfeit products following two customer complaints in England in March. The company immediately informed the local regulatory authorities in the UK, launched an investigation and increased monitoring of complaints.
This article is mentioned on the Diabetes.co.uk Home page, but HERE IS THE DETAILED NOVO NORDISK ARTICLE.